迈克生物: 关于2024年限制性股票激励计划预留权益失效的公告

Core Points - The company announced the expiration of reserved rights for the 2024 restricted stock incentive plan due to the failure to determine the incentive objects within the stipulated time frame [1][5] - The total number of reserved restricted stocks was adjusted from 817,400 shares to 870,900 shares, which accounts for 10.65% of the total rights to be granted under the incentive plan [1][3] - The company has completed the necessary approval procedures for the incentive plan, including obtaining shareholder approval and board authorization [2][3] Summary of Relevant Sections Approval Procedures - The company held a shareholder meeting to approve the draft of the 2024 restricted stock incentive plan and related proposals [2] - The independent director acted as a collector for the voting rights of shareholders regarding the incentive plan [2] - The supervisory board verified the incentive object list and issued opinions on the related matters [2][3] Expiration of Reserved Rights - According to regulations, if the incentive objects are not determined within 12 months after the plan's approval, the reserved rights will expire [5] - As of the announcement date, the reserved 870,900 shares had not had their incentive objects determined, leading to their expiration [5] Impact on the Company - The expiration of the reserved rights will not affect the company's capital structure or have a significant impact on its operational and financial status [5] - The management team is expected to continue fulfilling their responsibilities and creating value for shareholders [5]